Pfizer – Accelerating biomarker testing for optimized metastatic colorectal cancer treatment planning across Canada RFP
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with unit
Memorial Deadline: Thursday 10th, April 2025
External Deadline: Thursday 17th, April 2025
Description
Pfizer’s Global Medical Grants & Partnerships (GMGP) supports the global healthcare community’s independent initiatives, e.g., research, quality improvement or education, to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Colorectal Cancer Canada (CCC) is Canada’s patient led not-for-profit patient association dedicated to colorectal cancer awareness and education, support for patients and their caregivers, and advocacy on their behalf and aspires to reduce the incidence and mortality of colorectal cancer in Canada while improving the quality of life of patients, their families and their caregivers. Founded in 1998, CCC has been an advocate for Canadian CRC patients for over twenty-five years. Through the Get Personal project and numerous other educational initiatives, CCC has prioritized the improvement of timely access to molecular testing for Canadian mCRC patients among its many important objectives.
For all Research and QI proposals, the grant requester and ultimately, the grantee, is responsible for the design, implementation, sponsorship and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. As the commercial supporter, Pfizer colleagues must not be involved in any aspect of project development or implementation.
Date RFP Issued: January 22, 2025
Geographic Scope: Canada
Clinical Area: Metastatic colorectal cancer (mCRC)
Link to full RFP: Accelerating biomarker testing for optimized metastatic colorectal cancer treatment planning across Canada
Application Due Date: April 17, 2025
Specific Area of Interest: The intent of this RFP is to encourage the applicant Canadian organizations and institutions to pursue innovative approaches for Research or QI projects that aim to optimize molecular testing for patients in metastatic CRC at the applicants’ centre. Applicants are invited to implement innovative ideas with the goal of creating a path for sustainable molecular testing for cancer patients in Canada.
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Don Rodriguez (don.rodriguez@pfizer.com).